Literature DB >> 26130513

Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.

Salyka Sengsayadeth1, Bipin N Savani2, Didier Blaise3, Florent Malard4, Arnon Nagler5, Mohamad Mohty6.   

Abstract

Acute myeloid leukemia is the most common indication for an allogeneic hematopoietic cell transplant. The introduction of reduced intensity conditioning has expanded the recipient pool for transplantation, which has importantly made transplant an option for the more commonly affected older age groups. Reduced intensity conditioning allogeneic transplantation is currently the standard of care for patients with intermediate or high-risk acute myeloid leukemia and is now most often employed in older patients and those with medical comorbidities. Despite being curative for a significant proportion of patients, post-transplant relapse remains a challenge in the reduced intensity conditioning setting. Herein we discuss the studies that demonstrate the feasibility of reduced intensity conditioning allogeneic transplants, compare the outcomes of reduced intensity conditioning versus chemotherapy and conventional myeloablative conditioning regimens, describe the optimal donor and stem cell source, and consider the impact of post-remission consolidation, comorbidities, center experience, and more intensive (reduced toxicity conditioning) regimens on outcomes. Additionally, we discuss the need for further prospective studies to optimize transplant outcomes. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26130513      PMCID: PMC4486220          DOI: 10.3324/haematol.2015.123331

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  97 in total

1.  Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation.

Authors:  Christoph Schmid; Myriam Labopin; Arnon Nagler; Dietger Niederwieser; Luca Castagna; Reza Tabrizi; Michael Stadler; Jürgen Kuball; Jan Cornelissen; Jiri Vorlicek; Gerard Socié; Michele Falda; Lars Vindeløv; Per Ljungman; Graham Jackson; Nicolaus Kröger; Andreas Rank; Emmanuelle Polge; Vanderson Rocha; Mohamad Mohty
Journal:  Blood       Date:  2011-12-13       Impact factor: 22.113

2.  Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.

Authors:  Vincent T Ho; Haesook T Kim; Julie Aldridge; Deborah Liney; Grace Kao; Philippe Armand; John Koreth; Corey Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; Edwin P Alyea
Journal:  Biol Blood Marrow Transplant       Date:  2010-12-27       Impact factor: 5.742

3.  Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.

Authors:  Betul Oran; John E Wagner; Todd E DeFor; Daniel J Weisdorf; Claudio G Brunstein
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-11       Impact factor: 5.742

Review 4.  Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need.

Authors:  Avichai Shimoni; Arnon Nagler
Journal:  Best Pract Res Clin Haematol       Date:  2011-06-24       Impact factor: 3.020

5.  Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors.

Authors:  N S Majhail; C G Brunstein; R Shanley; K Sandhu; B McClune; B Oran; E D Warlick; J E Wagner; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  2011-05-23       Impact factor: 5.483

6.  Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.

Authors:  John R Wingard; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Kathleen A Sobocinski; David Jacobsohn; Mohamed L Sorror; Mary M Horowitz; Brian Bolwell; J Douglas Rizzo; Gérard Socié
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

7.  Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Authors:  Robert J Soiffer; Jennifer Lerademacher; Vincent Ho; Fangyu Kan; Andrew Artz; Richard E Champlin; Steven Devine; Luis Isola; Hillard M Lazarus; David I Marks; David L Porter; Edmund K Waller; Mary M Horowitz; Mary Eapen
Journal:  Blood       Date:  2011-04-04       Impact factor: 22.113

8.  Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.

Authors:  Gheath Alatrash; Marcos de Lima; Nelson Hamerschlak; Matteo Pelosini; Xuemei Wang; Lianchun Xiao; Fabio Kerbauy; Alexandre Chiattone; Gabriela Rondon; Muzaffar H Qazilbash; Sergio A Giralt; Leandro de Padua Silva; Chitra Hosing; Partow Kebriaei; Weiqing Zhang; Yago Nieto; Rima M Saliba; Richard E Champlin; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2011-02-18       Impact factor: 5.742

9.  Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.

Authors:  Wael Saber; Shaun Opie; J Douglas Rizzo; Mei-Jie Zhang; Mary M Horowitz; Jeff Schriber
Journal:  Blood       Date:  2012-02-10       Impact factor: 22.113

10.  Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.

Authors:  S M Luger; O Ringdén; M-J Zhang; W S Pérez; M R Bishop; M Bornhauser; C N Bredeson; M S Cairo; E A Copelan; R P Gale; S A Giralt; Z Gulbas; V Gupta; G A Hale; H M Lazarus; V A Lewis; M C Lill; P L McCarthy; D J Weisdorf; M A Pulsipher
Journal:  Bone Marrow Transplant       Date:  2011-03-28       Impact factor: 5.483

View more
  22 in total

1.  GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.

Authors:  A Nazha; L Rybicki; D Abounader; B Bolwell; R Dean; A T Gerds; D Jagadeesh; B K Hamilton; B T Hill; M Kalaycio; H Liu; B Pohlman; R Sobecks; M A Sekeres; N S Majhail
Journal:  Bone Marrow Transplant       Date:  2016-10-10       Impact factor: 5.483

2.  How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT.

Authors:  Olaf Penack; Christophe Peczynski; Mohamad Mohty; Ibrahim Yakoub-Agha; Jan Styczynski; Silvia Montoto; Rafael F Duarte; Nicolaus Kröger; Hélène Schoemans; Christian Koenecke; Zinaida Peric; Grzegorz W Basak
Journal:  Blood Adv       Date:  2020-12-22

Review 3.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

4.  Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.

Authors:  Alexandros Spyridonidis; Myriam Labopin; Bipin N Savani; Riitta Niittyvuopio; Didier Blaise; Charles Craddock; Gerard Socié; Uwe Platzbecker; Dietrich Beelen; Noel Milpied; Jan J Cornelissen; Arnold Ganser; Anne Huynh; Laimonas Griskevicius; Sebastian Giebel; Mahmoud Aljurf; Eolia Brissot; Florent Malard; Jordi Esteve; Zinaida Peric; Frédéric Baron; Annalisa Ruggeri; Christoph Schmid; Maria Gilleece; Norbert-Claude Gorin; Francesco Lanza; Roni Shouval; Jurjen Versluis; Gesine Bug; Yngvar Fløisand; Fabio Ciceri; Jamie Sanz; Ali Bazarbachi; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2020-01-29       Impact factor: 5.483

5.  Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.

Authors:  Bipin N Savani; Myriam Labopin; Nicolaus Kröger; Jürgen Finke; Gerhard Ehninger; Dietger Niederwieser; Rainer Schwerdtfeger; Donald Bunjes; Bertram Glass; Gerard Socié; Per Ljungman; Charles Craddock; Frédéric Baron; Fabio Ciceri; Norbert Claude Gorin; Jordi Esteve; Christoph Schmid; Sebastian Giebel; Mohamad Mohty; Arnon Nagler
Journal:  Haematologica       Date:  2016-03-11       Impact factor: 9.941

6.  Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.

Authors:  Arnon Nagler; Myriam Labopin; Bhagirathbhai Dholaria; Riitta Niittyvuopio; Johan Maertens; Xavier Poiré; Jan Cornelissen; Péter Reményi; Jean Henri Bourhis; Yves Beguin; Ram Malladi; Tessa Kerre; Wilfried Schroyens; Bipin N Savani; Mohamad Mohty
Journal:  Blood Adv       Date:  2019-07-09

7.  Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.

Authors:  Bipin N Savani; Myriam Labopin; Didier Blaise; Dietger Niederwieser; Fabio Ciceri; Arnold Ganser; Renate Arnold; Boris Afanasyev; Stephane Vigouroux; Noel Milpied; Michael Hallek; Jan J Cornelissen; Rainer Schwerdtfeger; Emmanuelle Polge; Frédéric Baron; Jordi Esteve; Norbert C Gorin; Christoph Schmid; Sebastian Giebel; Mohamad Mohty; Arnon Nagler
Journal:  Haematologica       Date:  2015-11-12       Impact factor: 9.941

Review 8.  Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia.

Authors:  Rebecca Levin-Epstein; Caspian Oliai; Gary Schiller
Journal:  Curr Treat Options Oncol       Date:  2018-10-25

9.  Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.

Authors:  Takuya Yamashita; Akiyoshi Takami; Naoyuki Uchida; Takahiro Fukuda; Tetsuya Eto; Souichi Shiratori; Shuichi Ota; Takashi Akasaka; Shigesaburo Miyakoshi; Tadakazu Kondo; Michihiro Hidaka; Junya Kanda; Yoshiko Atsuta; Shingo Yano
Journal:  Bone Marrow Transplant       Date:  2020-03-12       Impact factor: 5.483

10.  First Multimodal, Three-Dimensional, Image-Guided Total Marrow Irradiation Model for Preclinical Bone Marrow Transplantation Studies.

Authors:  Darren Zuro; Srideshikan Sargur Madabushi; Jamison Brooks; Bihong T Chen; Janagama Goud; Amandeep Salhotra; Joo Y Song; Liliana Echavarria Parra; Antonio Pierini; James F Sanchez; Anthony Stein; Monzr Al Malki; Marcin Kortylewski; Jeffrey Y C Wong; Parham Alaei; Jerry Froelich; Guy Storme; Susanta K Hui
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-06-11       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.